Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer

Breast Cancer Research and Treatment

Volumn 99, Issue 1, 2006, Pages 85-90

  Rodríguez Pinilla, Socorro María ^a   Honrado, Emiliano ^a   Hardisson, David ^b   Benítez, Javier ^a   Palacios, José ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Basal like phenotype; Breast cancer; Caveolin; Tissue microarray

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CAVEOLIN 1; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ARTICLE; BASAL CELL; BREAST CANCER; CANCER CLASSIFICATION; CAVEOLA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FAMILIAL CANCER; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TISSUE FIXATION; TISSUE MICROARRAY; TISSUE SECTION;

BREAST NEOPLASMS; CARCINOMA; CAVEOLIN 1; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MODELS, STATISTICAL; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE;

EID: 33746708760     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9184-1     Document Type: Article

References (44)

1. Williams TM, Lisanti MP: Protein family review. The caveolin proteins. Genome Biol 5: 214-222, 2004
2. Couet J, Belanger MM, Roussel E, Drolet MC: Cell biology of caveolae and caveolin. Adv Drug Deliv Rev 49: 223-235, 2001
3. Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, Ren C, Wang J, Tahir SA, Thompson TC: Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 61: 4386-4392, 2001
4. Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, Belldegrun A: Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J 6: 220-233, 2000
5. Fine SW, Lisanti MP, Galbiati F, Li M: Elevated expression of caveolin-1 in adenocarcinoma of the colon. Am J Clin Pathol 115: 719-724, 2001
6. Hu YC, Lam KY, Law S, Wong J, Srivastava G: Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC. Clin Cancer Res 7: 3519-3525, 2001
7. Kato K, Hida Y, Miyamoto M, Hashida H, Shinohara T, Itoh T, Okushiba S, Kondo S, Katoh H: Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 15: 929-933, 2002
8. Ho CC, Huang PH, Huang HY, Chen YH, Yang PC, Hsu SM: Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol 161: 1647-1656, 2002
9. Wiechen K, Diatchenko L, Agoulnik A, Scharff KM, Schober H, Arlt K, Zhumabayeva B, Siebert PD, Dietel M, Schafer R, Sers C: Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol 159: 1635-1643, 2001
10. Sakamoto M, Kondo A, Kawasaki K, Goto T, Sakamoto H, Miyake K, Koyamatsu Y, Akiya T, Iwabuchi H, Muroya T, Ochiai K, Tanaka T, Kikuchi Y, Tenjin Y: Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell 14: 305-315, 2001
11. Wiechen K, Sers C, Agoulnik A, Arlt K, Dietel M, Schlag PM, Schneider U: Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am J Pathol 158: 833-839, 2001
12. Hurlstone AFL, Reid G, Reeves JR, Fraser J, Strathdee G, Rahilly M, Parkinson E K, Black DM: Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines. Oncogene 18: 1881-1890, 1999
13. Hayashi K, Matsuda S, Machida K, Yamamoto T, Fukuda Y, Nimura Y, Hayakawa T, Hamaguchi M: Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res 61: 2361-2364, 2001
14. Hino M, Doihara H, Kobayashi K, Aoe M, Shimizu N: Caveolin-1 as tumor suppressor gene in breast cancer. Surg Today 33: 486-490, 2003
15. Williams TM, Cheung MW, Park DS, Razani B, Cohen AW, Muller WJ, Di Vizio D, Chopra NG, Pestell RG, Lisanti MP: Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Mol Biol Cell 14: 1027-1042, 2003
16. Chen ST, Lin SY, Yeh KT, Kuo SJ, Chan WL, Chu YP, Chang JG: Mutational, epigenetic and expressional analyses of caveolin-1 gene in breast cancers. Int J Mol Med 14: 577-582, 2004
17. Williams TM, Medina F, Badano I, Kazan RB, Hutchinson J, Muller WJ, Chopra NG, Scherer PE, Pestell RG, Lisanti MP: Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 279: 51630-51646, 2004
18. Sloan EK, Stanley KL, Anderson RL: Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene 23: 7893-7897, 2004
19. Sagara Y, Mimori K, Yoshinaga K, Tanaka F, Nishida K, Ohno S, Inoue H, Mori M: Clinical significance of caveolin-1, caveolin-2 and Her2/neu mRNA expression in human breast cancer. Br J Cancer 91: 959-965, 2004
20. Park S-S, Kim JE, Kim YA, Kim YC, Kim S-W: Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast. Histopathology 47: 625-630, 2005
21. Van den Eynden GG, Laere SJV, Van der Auwera I, Merajver SD, Van Marck EA, van Dam P, Vermeulen PB, Dirix LY, van Golen KL: Overexpression of caveolin-1 and -2 in cell lines and in human simples of inflammatory breast cancer. Breast Cancer Res Treat 22: 1-10, 2005
22. Jones C, Mackay A, Grigoriadis A, Cossu A, Reis-Filho JS, Fulford L, Dexter T, Davies S, Bulmer K, Ford E, Parry S, Budroni M, Palmieri G, Neville AM, O'Hare MJ, Lakhani SR: Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res 64: 3037-3045, 2004
23. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000
24. Gusterson BA, Ross DT, Heath VJ, Stein T: Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 7: 143-148, 2005
25. Tsuda H, Takarabe T, Hasegawa F, Fukutomi T, Hirohashi S: Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 24: 197-202, 2000
26. Jacquemier J, Padovani L, Rabayrol L, Lakhani SR, Penault-Llorca F, Denoux Y, Fiche M, Figueiro P, Maisougrosse V, Ledonssal V, Martinez Penuela J, Vdvarhely N, El Makdissi G, Ginestier C, Geneix J, Charafe-Jauffret E, Xerri L, Eisinger F, Birnbaum D, Sobol H: Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 207: 260-268, 2005
27. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Modern Pathol 19: 264-271, 2006
28. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matesse JC, Brown PO, Botstein D, Eystein-Lonning P, Borresen- Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001
29. Van't Veer LJ, Dal H, van de Vijver MJ, He YD, Hart AA, Mao M, Meterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-535, 2002
30. Rouzier N, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11: 5678-5685, 2005
31. Rodríguez-Pinilla SM, Sarrío D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J: Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res, 12: 2006
32. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeler J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423, 2003
33. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Kramling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JG, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, Jacquemier J, Wagner T, Peto J, Stratton MR, McGuffong L, Easton DF: Breast Cancer linkage consortium. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11: 5175-5180, 2005
34. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressier L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374, 2004
35. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, Rodríguez S, Cigudosa JC, Diez O, Alonso C, Lerma E, Dopazo J, Rivas C, Benitez J: Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 90: 5-14, 2005
36. Honrado E, Benitez J, Palacios J: The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol 18: 1305-1320, 2005
37. Sontiriou C, Neo S-Y, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100: 10393-10398, 2003
38. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adélaïde J, Cervera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D, Bertucci F: Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 24: 1-12, 2005
39. Sunaga N, Miyajima K, Suzuki M, Sato M, White MA, Ramirez RD, Shay JW, Gazdar AF, Minna JD: Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res 64: 4277-4285, 2004
40. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, Thompson TC: Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 4: 1873-1880, 1998
41. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95: 1482-1485, 2003
42. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Begin LR, Hamel N, Goffin JR, Wong N, Trudel M, Kapusta L, Porter P, Akslen LA: The prognostic implication of the basal-like (cyclin-E high/p27 low/p53+/ glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancers. Cancer Res 64: 830-835, 2004
43. van der Groep P, Bouter A, van der Zanden R, Menko FH, Buerger H, Verheijen RH, van der Wall E, van Dieest PJ: Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 96: 712-713, 2004
44. Palacios J, Honrado E, Osorio A, Diez O, Rivas C, Benitez J: Re: Germline mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 96: 712-714, 2004